#Sustainability #USA #LabConnect #Johnson City #Kits4Life

LabConnect Partners with Kits4Life to Minimize Kit Waste

August 7, 2025 — Johnson City, Tennessee
As part of its unwavering commitment to environmental stewardship, LabConnect has announced a strategic alliance with Kits4Life, a project led by the MedSurplus Alliance. This innovative partnership signifies LabConnect's dedication to sustainable clinical research while adhering to its extensive environmental, social, and governance (ESG) strategy.

Through this collaboration, LabConnect aims to work closely with sponsors and clinical sites to identify specimen collection kits that can be repurposed, ultimately reducing the amount of waste that ends up in landfills and contributing to greater health equity globally. It is widely recognized that clinical trials are vital to the advancement of transformative therapies. However, they also generate substantial amounts of waste, particularly from unused or expired materials that often contain high-quality medical supplies. When these items are ethically redirected, they have the potential to vastly improve healthcare access in underserved communities.

“Partnering with Kits4Life provides us with an effective framework to recover surplus clinical trial kits while ensuring their safe and ethical donation to organizations in need,” stated Julia Tarasenko, Chief Commercial Strategy Officer at LabConnect. This initiative places value on societal responsibility, with LabConnect striving to turn waste into helpful resources rather than allowing them to contribute to environmental degradation.

LabConnect is dedicated to transforming the clinical trial model, making it more sustainable and inclusive on a global scale. The company's ESG strategy encompasses several key priorities, including reducing carbon footprints, ensuring ethical sourcing, and promoting community engagement. The collaboration with Kits4Life represents an actionable step toward minimizing waste and nurturing positive impacts in local communities.

“Both sustainability and scientific innovation should coexist, bolstering each other rather than existing in isolation,” Tarasenko added. “As the industry evolves, collaborations like this one set a precedent for a future where environmental responsibility aligns with the pursuit of groundbreaking therapies.”

About LabConnect

LabConnect stands at the forefront of Central Laboratory Services, offering FSP (Functional Service Provider) capabilities, scientific consulting, and services for data integration and transformation. The company specializes in complex studies, including immuno-oncology, cellular and gene therapies, and rare or orphan diseases.

With a combination of state-of-the-art technology, leading laboratories, and accessibility to major and emerging markets, LabConnect provides a comprehensive solution for drug development companies, optimizing their central laboratory needs.

For more information, visit LabConnect's website and follow them on LinkedIn for updates about their initiatives and services.